Ulrich Neumann, MBA MSc MAFeb 20, 20206 minCan we afford to pay for future cures?Pharmaceutical R&D is racing ahead of our health system's ability to adjust payment models, but innovative concepts are finally emerging.
Ulrich Neumann, MBA MSc MANov 14, 20196 minPrescription Drug Pricing: “The Times They Are A Changin”The drug pricing debate in DC has intensified, and the pharmaceutical industry has become the prime target of bipartisan outrage.
Ulrich Neumann, MBA MSc MAOct 9, 201910 min'ICER' strikes again - Scandal time?The drug-price watchdog ICER just issued a "Report on Unsupported Price Increases". The 'study' made the headlines, but it is problematic.
Ulrich Neumann, MBA MSc MAMay 31, 20195 minReal World Evidence: From Market Access to Drug ApprovalThis analysis outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make the industry.
Ulrich Neumann, MBA MSc MAFeb 3, 20184 minBlockchain in Pharma... Blockchain for Market Access? - 5 Thoughts5 observations as to where we are today, and what might lie ahead for Blockchain in Pharmaceutical Market Access.